v3.25.2
Consolidated Statements of Cash Flows - CAD ($)
$ in Thousands
 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Operating activities    
Net income (loss) from continuing operations $ 15,763 $ (57,083) [1]
Adjustments for non-cash items:    
Unrealized gain on changes in fair value of biological assets (175,361) (134,588) [2]
Changes in fair value of inventory and biological assets sold 141,807 80,546 [1]
Depreciation of property, plant and equipment 21,952 31,874 [2]
Amortization of intangible assets 595 901 [2]
Share-based compensation 11,524 12,717 [2]
Impairment of property, plant and equipment 696 4,042 [2]
Impairment of intangible assets and goodwill 0 32,856 [2]
Net interest accrual and accretion 2,465 7,923 [2]
Interest and other income 0 (33) [2]
Deferred tax recovery (3,190) (1,667) [2]
Other gains (607) (29,091) [2]
Foreign exchange gain (loss) (11,453) 171 [2]
Deferred compensation amortization 3,805 3,807 [2]
Cash provided by (used in) operating activities from continuing operations before changes in non-cash working capital 7,996 (47,625) [2]
Changes in non-cash working capital 10,210 (15,541) [2]
Net cash provided by (used in) operating activities from continuing operations 18,206 (63,166) [2]
Net cash used in operating activities from discontinued operations (2,201) (5,342) [2]
Net cash provided by (used in) operating activities 16,005 (68,508) [2]
Investing activities    
Proceeds from derivative asset and marketable securities 5,488 4,993 [2]
Purchase of property, plant and equipment and intangible assets (18,859) (16,834) [2]
Proceeds from disposal of property, plant and equipment and assets held for sale 2,034 12,276 [2]
Changes in restricted cash (4,282) 2,124 [2]
Acquisition of businesses, net of cash acquired 0 (2,539) [2]
Payment of contingent consideration 0 (3,006) [2]
Cash used in investing activities from continuing operations (15,619) (2,986) [2]
Net cash provided by (used in) investing activities from discontinued operations 1,292 (377) [2]
Net cash used in investing activities (14,327) (3,363) [2]
Financing activities    
Proceeds from loans and borrowings 11,680 14,544 [2]
Repayment of loans and borrowings (7,245) (3,042) [2]
Repayment of convertible debenture 0 (91,635) [2]
Net principal payments of lease liabilities (5,240) (5,239) [2]
Shares issued for cash, net of issuance costs 0 37,924 [2]
Proceeds from stock option exercise 820 0 [2]
Cash used in financing activities from continuing operations 15 (47,448) [2]
Net cash used in financing activities from discontinued operations (131) (475) [2]
Net cash used in financing activities (116) (47,923) [2]
Effect of foreign exchange on cash and cash equivalents 264 297 [2]
Increase (decrease) in cash and cash equivalents 1,826 (119,497) [2]
Cash and cash equivalents, beginning of period [2] 136,095 255,592
Cash and cash equivalents, end of period $ 137,921 $ 136,095 [2]
[1] Comparative information has been adjusted due to discontinued operations see Note 8(b).
[2] Comparative information has been adjusted due to discontinued operations see Note 8(b).